Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Lockheed Martin (LMT) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Lockheed Martin between January 23, 2024 and July 21, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a n ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sable Offshore (SOC) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Sable Offshore between May 19, 2025 and June 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a national ...

SAN FRANCISCO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- A new class-action lawsuit is targeting KBR, Inc. (NYSE: KBR), alleging the company made misleading statements to investors in the weeks leading up to the abrupt cancellation of a major military contract. The suit, Norrman v. KBR, Inc., et al., No. 4:25-cv-04464 (S.D. Tex.), was filed after the company’s stock plunged following the termination of a multi-billion-dollar deal. National shareholders rights firm Hagens Berman urges KBR investors who suffered sub ...

Accessibility StatementSkip Navigation MILWAUKEE, Sept. 25, 2025 /PRNewswire/ -- The Ademi Firm is investigating First Savings (Nasdaq: FSFG) for possible breaches of fiduciary duty and other violations of law in its transaction with First Merchants. The transaction agreement unreasonably limits competing transactions for First Savings by imposing a significant penalty if First Savings accepts a competing bid. We are investigating the conduct of the First Savings board of directors, and whether they are ful ...

Accessibility StatementSkip Navigation MILWAUKEE, Sept. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating IAS (Nasdaq: IAS) for possible breaches of fiduciary duty and other violations of law in its transaction with Novacap. Shareholders of IAS will receive $10.30 per share in a transaction valued at approximately $1.9 billion. IAS insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for IAS by impo ...

SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP has launched an investigation into whether the board members of Integral Ad Science Holding Corp. (NASDAQ: IAS) breached their fiduciary duties in connection with the proposed sale of the company to private equity firm Novacap. Background On September 24, 2025, Integral Ad Science Holding Corp. (“IAS”) and Novacap announced that they had entered into a definitive merger agreement under which Novacap will acquire ...

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Capricor Therapeutics, Inc. (NASDAQ: CAPR) shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors. Investors who have continuously held Capricor shares since before October 9, 2024, may have legal rights and are encouraged to contact the firm to learn more:https://www.johnsonfistel.com/investigations/capricor-therape ...

SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached their fiduciary duties in connection with the proposed sale of the Company to Pfizer, Inc. (NYSE: PFE). Background: On September 21, 2025, Metsera and Pfizer entered into a definitive merger agreement. Under the terms of the agreement, holders of Metsera’s common stock will receive $47.50 per share in cash. In a ...

公司动态 - Gross Law Firm向Unicycive Therapeutics Inc (NASDAQ: UNCY)股东发布通知 [1]

股价下跌事件 - 2025年8月28日 Telix Pharmaceuticals美国存托凭证价格下跌约16% 因FDA要求提供更多关于肾癌检测药物数据[1] - 2025年7月22日 公司披露收到SEC传票后 次日ADS价格下跌10%[1] - 上述事件均导致Telix ADS价格大幅下挫[4] 监管调查进展 - SEC正在调查公司关于前列腺癌治疗候选药物披露事项 调查于2025年7月22日盘后曝光[3] - 律师事务所Hagens Berman正在调查公司是否就药物候选品的开发及商业前景误导投资者[4] - 调查重点涉及前列腺癌治疗候选药物及肾癌检测药物的相关声明[2] 药物审批状况 - FDA针对Zircaix生物制剂许可申请发出完整回复函 该药物用于肾肿块诊断和透明细胞肾细胞癌特征分析[3] - CRL指出化学制造与控制方面存在缺陷 要求提供额外数据证明三期临床试验药物与商业生产流程可比性[3] - FDA向第三方制造和供应链合作伙伴发出缺陷通知 必须进行整改[3] 投资者参与渠道 - 遭受重大损失的投资者可联系律师事务所提交损失情况[2] - 掌握非公开信息者可通过SEC举报人计划提供协助 最高可获得SEC回收金额30%的奖励[6] - 律师事务所在此领域已获得超过29亿美元赔偿成果[7]